Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Point-of-Care, Biosensors & Mobile Diagnostics Europe 2020

Point-of-Care, Biosensors & Mobile Diagnostics Europe 2020 Agenda

Co-Located Conference Agendas

Lab-on-a-Chip and Microfluidics Europe 2020 | Organ-on-a-Chip, Tissue-on-a-Chip & Organoids Europe 2020 | Point-of-Care, Biosensors & Mobile Diagnostics Europe 2020 | 

Print Agenda

Wednesday, 9 September 2020


Conference Registration and Morning Coffee

Session Title: Conference Opening Session


Amy  ShenKeynote Presentation

Detection of Antibodies Against SARS-CoV-2 Spike Protein by Gold Nanospikes in an Optomicrofluidic Chip
Amy Shen, Professor and Provost, Okinawa Institute of Science and Technology Graduate University, Japan

The ongoing global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to active research in its associated diagnostics and medical treatments. While quantitative reverse transcription polymerase chain reaction (qRT--PCR) is the most reliable method to detect viral genes of SARS-CoV-2, serological tests for specific antiviral antibodies are also important as they identify false negative qRT--PCR responses, track how effectively the patient's immune system is fighting the infection, and are potentially helpful for plasma transfusion therapies. In this work, based on the principle of localized surface plasmon resonance (LSPR), we develop an optomicrofluidic sensing platform with gold nanospikes, fabricated by electrodeposition, to detect the presence and amount of antibodies specific to the SARS-CoV-2 spike protein in 1 uL of human plasma diluted in 1 mL of buffer solution, within ~30~min. The target antibody concentration can be correlated with the LSPR wavelength peak shift of gold nanospikes caused by the local refractive index change due to the antigen-antibody binding. This label-free microfluidic platform achieves a limit of detection of ~0.08~ng/mL (~0.5~pM), falling under the clinical relevant concentration range. We demonstrate that our opto-microfluidic platform offers a promising point-of-care testing tool to complement standard serological assays and make SARS-CoV-2 quantitative diagnostics easier, cheaper, and faster.


Lorena DiéguezKeynote Presentation

Using Microfluidics for Non-Invasive Cancer Diagnosis
Lorena Diéguez, Leader of the Medical Devices Research Group, INL- International Iberian Nanotechnology Laboratory, Portugal

Microfluidics presents numerous advantages for the handling of biological samples, as it provides careful control of fluids in the microscale. When it comes to biomarkers enrichment, microfluidics has demonstrated superior sensitivity and enhanced recovery compared to traditional methods. Incorporating sensors, lab-on-a-chip technologies offer efficient characterization of disease biomarkers from body fluids, making microfluidics ideal for clinical practice, enabling high throughput, portability, and automation. Early dissemination of cancer is difficult to detect by traditional imaging and pathological methods. While the presence of cancer material in body fluids is well known, current techniques for the isolation, analysis and characterization of these biomarkers are not efficient enough to be fully applied in clinical routine. In this talk, we present our work for isolation and multiplex analysis of cancer biomarkers from body fluids based on microfluidics, and biosensors towards personalized medicine and earlier diagnosis of cancer.


Robert VriesKeynote Presentation

Novel Organoid Models to Develop Drug Treatment Strategies
Robert Vries, CEO, HUB Organoids, Netherlands

Organoids such as IPSC derived brain organoids (Lancaster et al Nature 2013) or our adults epithelial stem cell derived organoids (Sato et al., Nature 2009, 2011) are proving to be a major breakthrough in preclinical models. The new patient like models are fundamental change in the way drug discovery and development can be performed. The development of the HUB Organoids started in the lab of Hans Clevers with the discovery of the identity of adult stem cells in human epithelial tissues such as intestine and liver (Barker et al., Nature 2007; Huch et al., Nature 2013). With the identification of these stem cells, we were able to develop a culture system that allowed for the virtually unlimited, genetically and phenotypically stable expansion of the epithelial cells from animals including humans, both from healthy and diseased tissue (Sato et al., Nature 2009, 2011; Gastroenterology 2011; Huch et al., Nature 2013, Cell 2015; Boj et al., Cell 2015).

We have now generated HUB organoid models from most epithelial organs. Recently, we and others have demonstrated that the in vitro response of organoids correlates with the clinical outcome of the patient from which the organoid was derived (Dekkers et al., Sci Trans Med 2016; Sachs et al., Cell 2018; Vlachogiannis et al., Science 2018). In addition, we have developed a coculture system using HUB Organoids and the immune system to study this interaction and drugs that target the role of the immune system in cancer and other diseases.

We have recently developed new models to study intestinal and lung barrier function and transport of the epithelium of these organs. These experiments show how organoids can be used to study mechanism that underly barrier function disruption in IBD or COPD. Furthermore, we have developed new models to study the interaction between immune system and epithelium. The combination of the new coculture models and assay development to study the epithelium allows us new insights into disease mechanisms and drug treatment strategies.


Morning Coffee Break and Networking in the Exhibit Hall


Valérie TalyKeynote Presentation

Droplet-based Microfluidics for Cancer Research
Valérie Taly, CNRS Research Director, Professor and Group leader Translational Research and Microfluidics, Université Paris Cité, France

Droplet-based microfluidics has led to the development of highly powerful tools with great potential in High-Throughput Screening where individual assays are compartmentalized within aqueous droplets acting as independent microreactors. Thanks to the combination of a decrease of assay volume and an increase of throughput, this technology goes beyond the capacities of conventional screening systems. Added to the flexibility and versatility of platform designs, such progresses in the manipulation of sub-nanoliter droplets has allowed to dramatically increase experimental level of control and precision. The presentation will aim at demonstrating through selected example, the great potential of this technology for biotechnology and cancer research. A first part of the presentation will exemplify how microfluidic systems can be used to compartmentalize and assay various types of cells without deleterious effects on their viability within complex and controlled platforms. The application of microfluidic systems for different cell-based assays will be demonstrated. Illustrative examples of droplet-based microfluidic platforms with high potential impact for cancer research will be presented. We will also show how by combining microfluidic systems and clinical advances in molecular diagnostic we have developed an original method to perform millions of single molecule PCR in parallel to detect and quantify a minority of target sequences in complex mixture of DNA with a sensitivity unreachable by conventional procedures. To demonstrate the pertinence of our procedures to overcome clinical oncology challenges, the results of clinical studies will be presented.


Emmanuel DelamarcheKeynote Presentation

Self-Coalescing Flows: A Powerful Method For Integrating Biochemical Reactions In Portable Diagnostic Devices
Emmanuel Delamarche, Manager Precision Diagnostics, IBM Research - Zürich, Switzerland

Diagnostics are ubiquitous in healthcare because they support prevention, monitoring, and treatment of diseases. Specifically, point-of-care diagnostics (POCDs) are particularly attractive for identifying diseases near patients, quickly, and in many settings and scenarios. POCDs can also trace exposure and acquired immunity of populations exposed to infectious diseases and screen metabolic deficiencies of individuals, who may be exposed to severe drug side effects. However, a long-standing challenge with POCDs is the need to integrate reagents in closed devices for a large number of potential applications. Following our previous contributions on developing capillary-driven microfluidic chips for highly miniaturized immunoassays, controlling and monitoring flow with nanoliter precision, and securing diagnostics against counterfeiting with dynamic optical security codes, we recently demonstrated how to shape and fold liquids inside microfluidic chambers to dissolve reagents with extreme precision. In this presentation, I will explain the underlying concept of this method, called self-coalescing flows, and will illustrate how it can be used to perform various assays, ranging from enzymatic assays, to immunoassays and molecular assays. Despite self-coalescing flows being still an open research topic in fluid physics, their implementation is surprisingly facile and robust and therefore may benefit the entire community working on POCDs.


Regina LuttgeKeynote Presentation

Nervous Systems-on-a-Chip: From Technology to Applied Biomedical Sciences
Regina Luttge, Professor, Eindhoven University of Technology, Netherlands

Challenges in eavesdropping on the complex cell signaling of the human central nervous system is an essential driver for the development of advanced in vitro technologies, called Brain-on-a-Chip. Developments in Brain-on-a-Chip technology focus primarily on the implementation of cortical cells from human stem cell source in a 3D cultured microenvironment. The aim of a recently launched EU project CONNECT is to mimic the in vivo functions of the nervous system in one connected chip system. The creation of new neurodegenerative disease models in this project brings together the knowledge accumulated among neuroscientists, stem cell experts and engineers to investigate the origins and possible treatments for Parkinson's disease. In this presentation, we will discuss in detail the technical approach of a nervous system on a chip as a unique tool for modelling the neural pathway of connected tissues on the brain-gut axis. In addition to design criteria for these microliter-sized physiological cell culture systems, the presentation will focus on guidance of the growth process of axon protrusions and the local control of cell differentiation processes while maintaining physiological conditions.


Networking Lunch in the Exhibit Hall, Exhibits and Poster Viewing

Session Title: Trends in Rapid and Point-of-Care Diagnostics


Integrating Aptamer Technology with Paper-Based Point-of-Care Devices for Biomedical Monitoring
John Brennan, Professor and Director, Biointerfaces Institute, McMaster University, Canada

DNA aptamers and DNA enzymes (denoted as functional nucleic acids or FNA) are an emerging platform for development of point-of-care (POC) diagnostic devices.  In this presentation, I will first focus on the development of new aptamers and DNA enzymes for a range of key biomarkers and their integration into colorimetric and fluorimetric assays for a variety of targets, mainly in the area of infectious disease.  Methods to couple target-binding to FNAs to the production of a DNA strand as an output will then be described.  The use the output DNA to directly initiate color production or produce isothermal amplification (ITA), will then be outlined.  Finally, the integration of the FNA assays into capillary flow-based paper devices will be described as platform for a range of new POC devices that allow facile detection of clinical analytes.  Examples will be provided outlining paper-based devices for ultra-sensitive detection of E. coli, C. difficile, MRSA and H. pylori.


Sensors For Continuous Biomolecular Monitoring
Menno Prins, Professor, Eindhoven University of Technology & Helia BioMonitoring, Netherlands


Winnie Edith SvendsenKeynote Presentation

Biosensor Systems For Bacterial Detection and Characterization
Winnie Edith Svendsen, Professor, Technical University of Denmark, Denmark

Bacteria can cause severe infections in humans and animals and are an increasing health risk due to the spreading of resistant strains that cannot be treated with antibiotics. A main source of bacteria infections is from contaminated surfaces, food or water, usually by inadequate cleaning of surfaces or by spills in drinking water. Bacteria concentrations are monitored closely, but for practical reasons monitoring is not continuous, which means that an infection source can sometimes remain undetected for several days. The development of sensors for fast and accurate detection of bacteria is therefore imperative. In this talk I will present various methods using micro and nanotechnology to detect, probe and characterize bacteria in different environments. The methods includes microfluidics based impedance flow cytometry, electrochemical methods and paper based microfluidic systems. The methods chosen depends on the environment in question.  I will demonstrate systems to count bacteria in swab samples or in water units with the potential to identify the viability state of the bacteria. I will touch upon detection and identification of bacteria in cow milk, pigfarms and human infections. Finally, I will discuss how to enhance the sensitivity of the sensors, using microfluidic systems combined with nanostructures through use of numerical simulations, and experimental integration.


Afternoon Coffee Break in the Exhibit Hall


Close of Day 1 of the Conference

Thursday, 10 September 2020


Morning Coffee

Session Title: Rapid, Mobile and Point-of-Care Diagnostics -- Current Opportunities in the Field


A Versatile Self-Powered Microfluidic Toolbox: From Sampling to Diagnosis to Therapeutics
Francesco Dal Dosso, Innovation Manager, KU Leuven, Belgium

At the Biosensors group, we have developed and applied a novel concept to manipulate liquids in a self-powered manner exploiting the advantages of paper- and channel-based microfluidics. This technology, termed (i)SIMPLE, can work both in withdraw and infusion mode being robust, inexpensive, easy to use and fabricate, addressing most of the requirements for a point-of-care (POC) test. Here, we demonstrate the versatility of this platform with 5 different applications: i) an easy to use and inexpensive self-sampling cartridge to precisely meter and dose  fingerprick blood droplets into dried blood spots, a gold standard method for remote sample collection, ii) an autonomous on-chip sample preparation device for blood to plasma separation with lab-quality performance, iii) a tunable and precise passive heating unit ideal for an isothermal amplification assay (i.e. RPA) compatible with many lab-on-a-chip approaches, iv) a chip capable of integrating a sandwich ELISA for POC therapeutic drug monitoring of adalimumab in chronic patients affected by autoimmune diseases (i.e. arthritis, Crohn’s) and v) an autonomous and controlled drug/vaccine delivery patch with integrated painless hollow microneedles.


Jonathan CooperKeynote Presentation

Mobile Diagnostics - Multiplexed DNA Malaria Sensing using Origami Paper Folding and Blockchain/Expert AI Digital Healthcare Systems
Jonathan Cooper, The Wolfson Chair of Bioengineering, University of Glasgow, United Kingdom

Identification of the species of pathogen is often key to informing the treatment of patients with infectious diseases. Here, we use paper-based folding, in a manner similar to origami, to process patient samples from a finger-prick of blood and diagnose malaria amongst communities in rural villages.   The design of the DNA sensing device means that testing can be done by a non-expert, integrating sample preparation into a multiplexed lateral flow device – akin to a conventional pregnancy test. We have tested our devices working with the Ministry of Health in Uganda, using a mobile phone to run the tests, collect and collate data and provide expert decision support for the healthcare workers. The technique has the potential to provide new diagnostic information that can direct therapy, thereby reducing the future threat of anti-microbial resistance.  The tests could also find applications in identifying asymptomatic carriers with low levels of infection, thereby supporting the delivery of disease elimination programmes.


Morning Coffee and Networking in the Exhibit Hall


Commercialization of Microfluidic Devices for Point-of-Care Applications
Vincent Linder, Founder and President, CDP BioMedical Consulting and CEO at Calciscon AG, Portugal

This presentation will focus on the commercialization challenges specific to microfluidic devices for point-of-care applications.  At an early stage of development, strategies can focus on de-risking analytical and clinical performances and may overlook other critical aspects of the design.  For a successful commercialization effort, it is essential to implement at the onset of the program a comprehensive vision encompassing the patient presenting in a POC setting, the POC user and all the steps needed to obtain an actionable test result.  This presentation will focus on development hurdles commonly experienced by microfluid-based IVD companies, and directions/solutions to overcome them.


The T50 Test for Improved Coordination of Interventions in Chronic Kidney Disease (CKD) Patients
Vincent Linder, Founder and President, CDP BioMedical Consulting and CEO at Calciscon AG, Portugal

Despite multiple drugs and diagnostics used today, most chronic kidney disease (CKD) patients still die of cardiovascular (CV) complications, and a prognosis for CKD patients is often as poor as that of some solid tumors.  Calciscon offers the T50 blood test to identify patients with elevated risk of CV complications.  Then, treating physicians use the T50 result to coordinate interventions, repeat the T50 to assess the efficacy of their intervention, and adjust treatment as needed until the T50 improves.  In this contribution we discuss the foundational work that led to the invention of the T50, and its clinical validation across multiple cohorts of CKD patients.


Jason HeikenfeldKeynote Presentation

Single Step and Fast Membrane Pre-Concentration for Continuous Biosensing and Point-of-Care Diagnostic Devices
Jason Heikenfeld, Professor and VP Operations, UC Office of Innovation, University of Cincinnati, United States of America

If there were a simple and passive technique, that would downshift the range of detection of all your sensors and analytes by 10-100X, what value would you place on such a breakthrough? Presented are single step and fast membrane pre-concentration devices for applications ranging from continuous wearable biosensing (sweat, interstitial fluid) to point of care diagnostics (blood, urine, saliva).  These devices now show >10X preconcentration in minutes for analytes ranging from small molecules (e.g. cortisol) to large proteins (influenza).  Further demonstrated are techniques that allow rapid adaptation of the devices for a wide variety of sensing modalities, including those sensitive to changes in pH or salinity.


Networking Lunch in the Exhibit Hall and Networking with Exhibitors


Optical Molecular Imaging and Sensing in Humans Using Chemical Probes
Mark Bradley, Professor of Therapeutic Innovation, Precision Healthcare University Research Institute, Queen Mary University of London, United Kingdom

The EPSRC Interdisciplinary Research Collaboration (IRC) ‘Proteus’ seeks to address the challenge of lung diseases by developing a chemistry and optical fibre based healthcare technology platform that combines physiological sensing with multiplexed optical molecular imaging. This technology enables in situ measurements in the distal lung to assess tissue function while generating and characterising unique signatures of pulmonary disease. In my talk I will describe the chemistry, the optical fibre technology and the CMOS SPAD detectors behind the teams optical imaging platforms and illustrate their in vivo application with the detection of bacterial infection deep in the human lung and the analysis of fibrosis.


Paper-based Analytical Devices for Therapeutic Drug Monitoring at the Point of Care
Jean-Manuel Segura, Professor, University of Applied Sciences and Arts Western Switzerland Valais, Switzerland

Therapeutic Drug Monitoring (TDM) allows for personalized dosage during therapeutic treatments and is often mandatory for modern potent drugs against cancer, infections or in organ transplantation cases. TDM can be performed either based on the analysis of a biomarker such as cholesterol testing in case of statin treatments or based on a quantification of the therapeutic drug itself. A prototypical example is the antibiotics tobramycin, which is often prescribed to neonates in case of bacterial infection and requires TDM to ensure efficacy while avoiding oto- and nephrotoxicity. Currently, the process of TDM is demanding for the patient as several milliliters of blood are required, is slow and costly due to the transfer of sample to a central laboratory, and suffers of limited efficacy owing to the difficulty to interpret the results for a non-specialist. Paper offers many advantages as a material to produce IVD tests as it is cheap, amenable for mass manufacturing, easy to dispose after performing the test and it provides many functionalities for designing a test such as capillary-driven motion of liquids. I will present our most recent results in developing various paper-based IVD tests for therapeutic drug monitoring at the point of care. A particular emphasis will be put on micro-PAD tests for the monitoring of therapeutic antibiotics in the blood and for the joint analysis of glucose and cholesterol.


Revealing the Secrets of Your Sweat
Annemarijn Steijlen, Researcher, Delft University of Technology, Netherlands

Development of a sweat sensing system and a validation strategy to reliably measure electrolyte variations and sweat rate during exercise


Close of Day 2 of the Conference

Add to Calendar ▼2020-09-09 00:00:002020-09-10 00:00:00Europe/LondonPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2020Point-of-Care, Biosensors and Mobile Diagnostics Europe 2020 in Rotterdam, The NetherlandsRotterdam, The